Not Yet RecruitingPhase 3

Enarodustat+CsA vs CsA in the Treatment of Newly-diagnosed TD-NSAA

90 participantsStarted 2026-04

Plain-language summary

This study aimed to compare the efficacy and safety of enarodustat combined with cyclosporine versus cyclosporine alone in the treatment of TD-NSAA.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Had no HLA-matched donors or was not suitable for first-line allogeneic hematopoietic stem cell transplantation (HSCT);
✕. With baseline liver and kidney functions \<2 ULN;
✕. ECOG score ≤ 2;
✕. Signed the informed consent;
✕. Had other primary or secondary bone marrow failure (BMF) diseases, such as Fanconi anemia, congenital keratinization disorder, etc.;
✕. With evidence of clonal hematological bone marrow diseases (MDS, AML) in cytogenetics;
✕. PNH clone ≥ 50%;
✕. Received HSCT before enrollment;

ORR

Timeframe: 6-month

NCT IDNCT07522996

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-12

Bing Han, Doctor